This technology is currently unpublished at the request of the university.
ATTAC™ Antigen-Targeted Therapy Against Cancer
A powerful new personalised anti-cancer vaccine program, based on the patient’s own cancer mutations
- Provisional patent applications are being developed that protect 1. The clinical monitoring of metastases development and 2. The method of determining the optimal personalized neoantigen selection.
- Commercial partner
- Development partner